1. Cyhoeddwyd

   The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

   Marson, A., Burnside, G., Appleton, R., Leach, J. P., Sills, G., Tudor-Smith, C., Plumpton, C., Hughes, D., Williamson, P., Baker, G. A., Balabanova, S., Taylor, C., Brown, R., Hindley, D., Howell, S., Maguire, M., Mohanraj, R. & Smith, P. E., 10 Ebr 2021, Yn: The Lancet. 397, 10282, t. 1375-1386

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

2. Cyhoeddwyd

   The all wales medicines strategy group: assessments and appraisals

   Hughes, D. & Hughes, D. A., 1 Tach 2008.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

3. Cyhoeddwyd

   The assessment, determinants & economics of medication compliance & persistence

   Hughes, D., Hughes, D. A., Gwadry Sridhar, F. & Elliott, R., 1 Hyd 2007.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

4. Cyhoeddwyd

   The cost-effectiveness of biological therapies for Crohn's disease: Markov cohort analyses incorporating UK patient-level cost data

   Hughes, D., Bodger, K., Kikuchi, T. & Hughes, D. A., 1 Maw 2008.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

5. Cyhoeddwyd

   The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data

   Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Mai 2008.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

6. Cyhoeddwyd

   The costs and cost-effectiveness of different service models of palliatice care, focusing on end of life care: A rapid review

   Spencer, L., Anthony, B., Davies, J., Pisavadia, K., Gillen, E., Noyes, J., Fitzsimmons, D., Lewis, R., Cooper, A., Hughes, D., Edwards, R. T. & Edwards, A., 7 Maw 2024, MedRxiv, 118 t.

   Allbwn ymchwil: Papur gweithio › Rhagargraffiad

7. Cyhoeddwyd

   The development of a QALY measure for epilepsy: NEWQOL-6D

   Hughes, D., Mulhern, B., Rowen, D., Jacoby, A., Marson, T., Snape, D., Hughes, D. A., Latimer, N., Baker, G. A. & Brazier, J. E., 1 Mai 2012, Yn: Epilepsy and Behavior. 24, 1, t. 36-43

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

8. Cyhoeddwyd

   The difference between effectiveness and efficacy of antimalarial drugs in Kenya.

   Hughes, D., Amin, A. A., Hughes, D. A., Marsh, V., Abuya, T. O., Kokwaro, G. O., Winstanley, P. A., Ochala, S. A. & Snow, R. W., 1 Medi 2004, Yn: Tropical Medicine and International Health. 9, 9, t. 967-974

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

9. Cyhoeddwyd

   The economics of evergreening.

   Hughes, D. & Hughes, D. A., 1 Ion 2009.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

10. Cyhoeddwyd

    The effect of compliance upon clinical effectiveness of chlorproguanil-dapsone (CD) and artemether-lumefantrine (AL) when compared to sulfadoxine-pyrimethamine (SP) for the treatment of uncomplicated falcipaum malaria in Malawi - a randomised controlled trial

    Hughes, D., Bell, D. J., Wootton, D., Mukaka, M., Montgomery, J., Kayange, N., Chimpeni, P., Zijlstra, E., Hughes D.A., N. V., Molyneux M.E.*, N. V., Ward, S. A., Winstanley, P. A. & Lalloo, D. G., 1 Tach 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

11. Cyhoeddwyd

    The experiences and perspectives of people with gout on urate self-monitoring

    Michael, T. J. F., Chan, J. S., Hughes, S., Wright, D. F. B., Coleshill, M. J., Hughes, D., Day, R. O., Aslani, P. & Stocker, S. L., Meh 2024, Yn: Health Expectations. 27, 3, 9 t., e14071.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

12. Cyhoeddwyd

    The future challenges

    Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 167-174

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

13. Cyhoeddwyd

    The impact of non-compliance on the cost-effectiveness of pharmaceuticals: A review of the literature.

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Hyd 2001, Yn: Health Economics. 10, 7, t. 601-615

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

14. Cyhoeddwyd

    The impact of parent treatment preference and other factors on recruitment: lessons learned from a paediatric epilepsy randomised controlled trial

    Carter, B., Bray, L., Al-Najjar, N., Tort Piella, A., Smith, C. T., Spowart, C., Collingwood, A., Crudgington, H., Currier, J., Hughes, D., Wood, E., Martin, R., Morris, C., Roberts, D., Rouncefield-Swales, A., Sutherland, H., Watson, V., Cook, G., Wiggs, L., Gringas, P. & Pal, D., 6 Chwef 2023, Yn: Trials. 24, 1, 83.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

15. Cyhoeddwyd

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Ion 2000, Yn: Value in Health. 3, 5, t. 373

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

16. Cyhoeddwyd

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Tach 2000.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

17. Cyhoeddwyd

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies.

    Hughes, D. & Hughes, D. A., 1 Ion 2001, 2001 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

18. Cyhoeddwyd

    The new and non-transparent Cancer Drugs Fund

    Wood, E. & Hughes, D., Ion 2020, Yn: PharmacoEconomics. 38, 1, t. 1-4

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

19. Cyhoeddwyd

    The pharmacokinetic profile of Warfarn: a systematic review

    Hughes, D., Al-Zubiedi S.*, N. V., Hughes D.A., N. V. & Pirmohamed, M., 1 Rhag 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

20. Cyhoeddwyd

    The population pharmacokinetics of lapdap

    Hughes, D., Ward, S., Simpson, J., Aarons, L., Szwandt, S. & Hughes, D. A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

21. Cyhoeddwyd

    The problem of orphan drugs

    Hughes, D., Ferner, R. E. & Hughes, D. A., 16 Tach 2010, Yn: British Medical Journal. 341, t. 335-341

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

22. Cyhoeddwyd

    The role of prevention in reducing the economic impact of ME/CFS in Europe: A report from the socioeconomics working group of the European Network on ME/CFS (EUROMENE).

    Pheby, D. F. H., Araja, D., Berkis, U., Brenna, E., Cullinan, J., de Korwin, J-D., Gitto, L., Hughes, D., Hunter, R. M., Trépel, D. & Wang-Steverding, X., 16 Ebr 2021, Yn: Medicina. 57, 4, 388.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

23. Cyhoeddwyd

    Trends and influences on use of antidiabetic drugs in England, 1992-2003.

    Walley, T., Hughes, D. & Kendall, H., 1 Tach 2005, Yn: Pharmacoepidemiology and Drug Safety. 14, 11, t. 769-773

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

24. Cyhoeddwyd

    Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?

    Hughes, D. & Hughes, D. A., 1 Tach 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

25. Cyhoeddwyd

    Understanding medication compliance and persistence from an economics perspective

    Hughes, D., Elliot, R. A., Shinogle, J. A., Peele, P., Bhosle, M. & Hughes, D. A., 1 Ion 2008, Yn: Value in Health. 11, 4, t. 600-610

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid